Abstract A series of 3-keto and 3-O-acyl derivatives of both 6-O-alkyl-8a-aza-8a-homoerythromycin A and 6-O-alkyl-9a-aza-9a-homo-erythromycin A were synthesised and tested against Gram-positive and Gram-negative bacteria. Derivatives of 8a-aza-8a-homoerythromycin A have potent antibacterial activity against not only azithromycin-susceptible strains, but also efflux (M) and inducible macrolide-lincosamide-streptogramin (iMLS B ) resistant Gram-positive pathogens, while the corresponding 9a-isomers were less active. Introduction of an additional ring such as 11,12-cyclic carbonate reduced antibacterial activity of both series. 3-Keto and 3-O-(4-nitrophenyl)-acetyl derivatives of 6-O-methyl-8a-aza-8a-homoerythromycin A show typical macrolide pharmacokinetics in preliminary in vivo studies in mice, and their in vivo efficacy is demonstrated.
Introduction
Second-generation macrolide antibiotics such as clarithromycin [1] (6-O-methylerythromycin A) and azithromycin [2, 3] (15-membered azalide) have been widely prescribed for upper and lower respiratory tract infections because of their superior antibacterial activity, pharmacokinetic properties and fewer gastrointestinal side effects compared to erythromycin A. However, the therapeutic utility of these macrolides has been severely compromised by the emergence of resistant pathogens [4] .
The discovery that the cladinose moiety was not absolutely necessary for good antibacterial activity [5] has opened up new areas on the macrolactone ring for SAR exploration. The next generation of macrolide antibiotics, e.g. ketolides, anhydrolides and acylides, all derived from 3-O-decladinosylerythromycin A, were identified over the past decade. The ketolide telithromycin (HMR 3647) [6] has gained market approval in EU and USA and cethromycin (ABT-773) [7] is in clinical development.
In this report, we describe a novel series of 3-keto and 3-O-acyl derivatives of both 8a-aza-8a-homoerythromycin A (8a-lactam) and 9a-aza-9a-homoerythromycin A (9a-lactam), that showed potent antibacterial properties against susceptible pathogens and improved activity against several species of efflux (M) and inducible (iMLS B ) macrolide resistant Gram-positive pathogens.
Chemistry
The synthetic route to 3-keto derivatives of 9a-and 8a-lactams is presented in Fig. 1 . Starting compounds for the synthesis were 6-O-alkylerythromycin A 9(E)-and 9(Z)-oximes [8, 9] . The Beckmann rearrangement of both oxime isomers was carried out with 4-toluenesulfonyl chloride in acetone-water solution at 0ϳ5°C to give corresponding 9a-(1aϳc) and 8a-(2aϳc) lactams. Subsequent removal of L-cladinose by treatment with aqueous HCl provided desired decladinosyl compounds (3aϳc and 4aϳc). A series of 3-ketolides were prepared by oxidation of 3-hydroxy group of 3aϳc and 4aϳc, using acetyl as 2Ј-hydroxy-protecting group. The oxidation was performed with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) in the presence of pyridine trifluoroacetate. Subsequent deprotection and purification by column chromatography gave desired 3-ketolides 5aϳc and 6aϳc.
Synthesis and Antibacterial Activity of Isomeric 15-Membered Azalides
Decladinosyl derivatives 3 and 4 having 2Ј-hydroxyprotecting group were also starting compounds for the preparation of 3-O-acyl derivatives. To prepare compounds 16 and 18ϳ32 mixed anhydrides, prepared from the corresponding carboxylic acid and pivaloyl chloride, were used followed by deprotection in methanol and purification by column chromatography, as shown in Fig. 2a for examples 16 and 18ϳ28 and Figure 2b for examples 29ϳ32. The only exception was synthesis of carbamate compound 17 that was prepared by reaction of 4a with 4-aminophenyl isocyanate.
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Fig. 3 Preparation of 3-keto and 3-O-acyl derivatives of 6-O-methyl-8a-aza-8a-and 9a-aza-9a-homoerythromycin A 11,12-cyclic carbonates. Table 1 13 C NMR data for 3-O-acyl-6-O-methyl-8a-lactams On the basis of previous reports [10] that the introductions of cyclic carbonate to the 11,12-position of macrolide derivatives enhanced the antibacterial activity, the 11,12-cyclic carbonate analogues were synthesized by known method [11, 12] . Key intermediates for compounds 11 and 12, 3-O-decladinosyl-carbonates 9 and 10, were obtained either from 1a and 2a, with hydrolytic cleavage of cladinose in the final step, or from 3-O-decladinosyl precursors 3a and 4a, which reacted with ethylene carbonate in the final step. Oxidation of 9 and 10 under condition described above for 5 and 6 provided 3-keto-11,12-carbonates 11 and 12, while acylation afforded 3-Oacyl-11,12-carbonates 13ϳ15, Fig. 3 .
MS and NMR spectra confirmed the structures of all compounds. For example, the 13 C NMR spectra of 3-hydroxy and 3-keto compounds revealed the shift of the C-3 signal in 3-hydroxy compounds 3aϳc, 4aϳc, 9 and 10 from around 78 ppm to the carbonyl signal around 206 ppm in compounds 5aϳc, 6aϳc, 11 and 12. The long-range coupling of H-2 and H-4 to this carbonyl group provided evidence that a new-formed carbonyl group was at C-3 position of the azalide ring.
Similar, acylation of 3-hydroxy group was indicated by appearance of new 13 C carboxylic signal around 170 ppm. The connectivity between this signal and H-3 in HMBC spectrum confirmed the position of acyl group in compounds 13ϳ32. The
13
C NMR data for 3-keto 5aϳc, 6aϳc and 3-O-acyl8a-lactam derivatives 16ϳ28 are summarized in Tables  1, 2 .
Results and Discussion
In vitro antibacterial activity of all compounds was determined against the panel of diverse bacterial stains, covering most important Gram- In all in vitro experiments we used azithromycin as reference compound to novel derivatives, being a "golden standard" in macrolide therapy, due to its superior stability, pharmacokinetic and safety properties over erythromycin A.
In Vitro Evaluation
The activities are reported in Tables 3ϳ5 as minimum inhibitory concentrations (MIC). First we studied a variety of 3-O-acyl 8-a-lactams (compounds 16ϳ28) and their activity is given in Table 3 . To probe the effect of the phenyl group on antibacterial activity we examined unsubstituted (28), 4-nitro substituted (24) and 4-methoxy substituted (26) phenyl derivatives. Compound 24, with electron withdrawing 4-nitro group, demonstrated the best antibacterial activity compared to unsubstituted phenyl ring, or phenyl ring substituted with electron-donating 4-methoxy group, with significant improvement over azithromycin against macrolide resistant strains (i.e. 2 mg/ml vs. Ͼ64 against MLSb S. aureus, ϭ0.013 mg/ml vs. 4 mg/ml against M S. pneumoniae, respectively).
Further we examined the effect of the chain length between macrolide skeleton and aryl ring, by introducing C1ϳC3 linkers (28, 27 and 16, respectively). Linker elongation decreased the antibacterial activity and the effect was most pronounced against S. aureus strains. Insertion of sulphur into the linker (19) did not influence activity substantially, while the presence of nitrogen atom in 17 resulted with diminished activity, especially against macrolide resistant strains.
Introduction of pyridyl ring (22 and 23), compared to phenyl ring (28), enhanced activity against macrolide sensitive strains, but decreases activity against macrolide resistant pathogens. The presence of naphthyl ring in 20 resulted in similar antimicrobial spectrum as 28, but increased activity against susceptible S. pyogenes.
As 4-nitrophenylacetyl derivative 24 was the most active 3-O-acyl derivative, we continued further chemical modification focusing on macrolide skeleton while maintaining this group at C-3 position. Consequently, 8a Table 2 13 C NMR data for 3-keto derivatives of 9a-and 8a-lactams and 9a-lactams, with or without 11,12-cyclic carbonate, having 6-OH or 6-O-C 1ϳ2 alkyl group were prepared, improved activity [10, 13] . Regarding alkylation at the 6-hydroxyl group, the best activity was shown by the compound with 6-O-methyl group (24). Overall, 6-Omethyl-3-O-acyl-8a-lactam (24) was found to be the most effective against all the pathogens tested. Furthermore, we examined compounds having 3-keto instead of 3-O-acyl group, with varying macrolide skeleton, Table 5 , and found that SAR is similar to 3-Oacyl series. The 6-O-methyl-8a-lactam (6a), which is a 3-keto counterpart of 24, displayed the best antibacterial activity.
Based on the above results of in vitro antibacterial activity, compounds 6a and 24 were selected for further pharmacokinetic and in vivo efficacy evaluation. In Vivo Evaluation Pharmacokinetic parameters in mice were determined in plasma and different tissues (liver, kidney, brain, spleen and lungs) for both selected derivatives and are given in Table 6 . The 3-keto compound 6a was very well and rapidly absorbed after oral administration in dose of 100 mg/kg. It achieved peak concentration 30 minutes after administration and showed high tissue accumulation with AUC (0ϳ4) levels relative to plasma AUC (0ϳ4) (AUC rel ) values ranging from 5.7 to 34.6. The only exception to this was brain level with AUC rel of 0.31. This is in accordance with behaviour of macrolides in general, as they are known to penetrate into cerebrospinal fluid very poorly [14] . High accumulation principally in liver tissue could be attributed to the first pass effect after oral administration, as all the blood from gut circulates through liver before going towards heart and other organs. Compound 6a has relatively short half-life around 2 hours, but its t 1/2 in plasma is prolonged (more than 5 hours), which might indicate high plasma protein binding. Due to low concentrations, t 1/2 for brain tissue could not be determined. The 3-O-acyl compound 24 was given orally at 50 mg/kg. It was well absorbed, but displayed moderate and more even tissue distribution than 6a, with AUC rel ranging from 1.4 to 3.6, with the exception of brain tissue where AUC rel was 0.28. Peak concentrations were reached 45 minutes after administration. Half-life was short, approximately one hour, with the exception of spleen, where it was prolonged to 2.4 hours.
Overall, both derivatives were well absorbed after p.o. administration in mice, had high peak concentrations, pronounced tissue accumulation and relatively short halflife. The 3-keto compound 6a was better absorbed and achieved significantly higher levels than the 3-O-acyl compound 24 in all organs examined, most markedly in liver where DNAUC (0ϳ4) was 20 times higher for 6a than for 24, and kidney, where 6a DNAUC (0ϳ4) was 7 times higher.
The in vivo efficacy of 6a, 24 and azithromycin was Table 7 . Compounds 6a and 24 where effective against ery-S S. aureus strains, but less than azithromycin, which could be correlated to corresponding in vitro activities, as well as differences in plasma half-lives (AZM t 1/2 being Ͼ12 hours [15] ). When tested against iMLS b resistant S. aureus strain, 6a and 24 were four times more effective than azithromycin.
Conclusion
In summary, we have identified a combination of structural factors that contribute to enhancement of antibacterial activity for novel 3-keto-and 3-O-acyl-azalides. These factors are 3-keto group or 3-O-acetyl group having the phenyl unit. In particular, phenyl unit bearing electronwithdrawing p-nitro group enhanced activity. Introduction of 11,12-cyclic carbonate substituent decreases activity of all tested compounds, as well as elongation of alkyl chain at 6-position of the lactam ring. Derivatives of 8a-lactam showed superior activity as compared to 9a-analogues. The encouraging in vivo results for 6a and 24 warrant further investigation to overcome MLS B -resistant pathogens and to develop potential next-generation azalides.
Experimental
General NMR spectra were recorded on a Bruker Avance DRX500 or Bruker Avance DPX300 spectrometer in CDCl 3 and chemical shifts are reported in ppm using TMS as an internal standard. Mass spectra were obtained on a Waters Micromass ZQ mass spectrometer for ES ϩ -MS. Silica gel chromatography was performed on Merck Kieselgel 60 and Merck TLC 60F 254 , respectively.
In general, organic layer was dried with anhydrous Na 2 SO 4 or K 2 CO 3 , evaporation and concentration were carried out under reduced pressure below 40°C, unless otherwise noted.
6-O-Ethyl-and 6-O-allylerythromycin 9-oxime derivatives were prepared from erythromycin 9(E)-oxime [9] according to the published procedure [8] which include protection, alkylation, deprotection and separation of obtained 9(E)-and 9(Z)-oxime isomers. 2Ј-O-Acetyl-protected derivatives were prepared by the known procedure [3, 16] .
Antibacterial Activity in Vitro
Strains were cultured on MH agar (Merck, Germany) except strains belonging to genus Streptococcus and Haemophilus, which were cultured on blood agar plates (Biomerioux, France) and chocolate agar plates (Biomerioux, France), respectively. Minimum inhibitory concentrations (MICs) were determined by the microtitre liquid dilution method as described by NCCLS [17] except that for Streptococcus medium, blood was substituted with 5% horse serum.
Pharmacokinetics in Mice
Experiments were carried out on male Balb/c mice (Charles River, Germany), weighing 20ϳ25 g, divided into groups, 6 mice each. Substances were administered p.o. to fasted mice as suspension in 0.5% carboxy -methylcellulose (w/v) (SIGMA) saline solution (0.9%) (PLIVA) at 100 mg/kg (6a) and 50 mg/kg (24). Blood and tissue samples (liver, kidney, lung, brain and spleen) were taken at 0.25, 0.5, 1, 2, 4, 6, 12, 24 and 48 hours after administration of 6a and at 0.25, 0.75, 1.5, 2, 3, 4, 6, 12, 24, 48 and 72 hours in case 24. The concentrations of the compounds were measured by microbiological agar diffusion method using Micrococcus luteus as test microorganism.
In Vivo Efficacy
In vivo efficacy of selected compounds was tested in S. aureus lethal septicaemia mouse model using Balb/c mice (Charles River, Germany), weighing 20ϳ25 g, divided into groups consisting of 10 mice each. Strains were grown overnight in MHB (Merck, Germany) at 37°C. Cells were suspended in fresh medium and the inoculum size (CFU/mouse) was adjusted to 1.0ϫ10 7 for both eryS (ATCC 29213) and iMLS B strains (Pliva Strain Collection Bacteria, PSCB 0009). Mice were infected by single i.v. administration. Therapy started 30 minutes after infection and daily p.o. doses were administered in two portions every 12 hours for 3 days. Compounds were dissolved in DMF (Merck, Germany) given as 0.5% carboxymethylcellulose (w/v) (SIGMA) saline solution (0.9%) (PLIVA) and 3% with respect to DMF. Survival was measured after 6 days. ED 50 values were calculated by inhouse log-probit method.
6-O-Methyl-9a-aza-9a-homoerythromycin A (1a) 6-O-Methylerythromycin A 9(E)-oxime (4.0 g, 0.005 mol) was dissolved in acetone (130 ml) and the solution was cooled to 0ϳ5°C. Subsequently, 4-toluenesulfonyl chloride (2.6 g, 0.01 mol) in acetone (40 ml) and sodium hydrogen carbonate (0.83 g, 0.01 mol) in water (130 ml) were added dropwise thereto within 1 hour under stirring. After stirring at room temperature for 8 hours, acetone was evaporated and aqueous solution was extracted with CHCl 3 by gradient extraction at pH 5 and 9. The combined organic layers at pH 9 were evaporated to give 1a (2.8 g, 70%) as a white solid. Compound 1a (2.8 g, 3.7 mmol) was dissolved in 0.25 N HCl (100 ml) and stirred at room temperature for 24 hours. To the reaction mixture CH 2 Cl 2 (50 ml) was added, pH was adjusted to 9.0 by adding conc. NH 4 OH and extracted with CH 2 Cl 2 (50 mlϫ3). The combined organic layers were washed with 10% aq. NaHCO 3 and water and evaporated under reduced pressure to give 3a (2.05 g, 92.3%). C-12), 71.2 (C-11), 70.6 (C-2Ј), 70.1 (C-5Ј) , 65.7 (C-3Ј), 57.8 (6-OCH 2 ES
Cl 2 (15 ml), DMSO (1.27 ml) and EDC (1.34 g, 7 mmol) were added. A solution of pyridine trifluoroacetate (1.37 g, 7 mmol) in CH 2 Cl 2 (5 ml) was added dropwise within 30 minutes at 15°C. After being stirred at room temperature for 3 hours, the reaction mixture was partitioned between CH 2 Cl 2 and brine and extracted at pH 9.5 with CH 2 Cl 2 (3ϫ20 ml). The organic extract was washed with brine and water, dried over K 2 CO 3 and concentrated under reduced pressure. The oily residue was dissolved in MeOH (30 ml) and stirred at room temperature for 24 hours. After evaporation of MeOH, the residue was purified by column chromatography (CH 2 Cl 2 -MeOH -NH 4 OH, 90 : 9 : 0.5) to give 5a in 83.1% yield. ES
By using this procedure (2Ј-O-acetylation, oxidation of 3-OH and 2Ј-deacetylation), the compounds 5bϳc and 6aϳc were prepared.
6-O-Ethyl-3-oxo-9a-aza-9a-homoerythromycin A (5b) The title compound was prepared starting from 3b in 31.4% yield. To a solution of 1a (3.0 g, 0.004 mol) in EtOAc (80 ml) ethylene carbonate (9.0 g, 0.102 mol) and K 2 CO 3 (9.0 g, 0.065 mol) were added. After stirring at reflux temperature for 12 hours, the reaction mixture was diluted with EtOAC (100 ml), washed with brine (100 ml) and then with H 2 O (100 ml). The evaporation of the organic solvent gave an oily residue, which was purified by silica gel column chromatography (CH 2 Cl 2 -MeOH -conc. NH 4 OH, 90 : 9 : 1.5) to afford 7 (2 g, 65%). The title compound was prepared from 7 in 87.2% yield according to the procedure used to prepare 3a.
The title compound was also prepared from 3a in 66.5% yield according to the procedure used to prepare 7. 13 (10) The title compound was prepared from 8 in 85.5% yield according to the procedure used to prepare 3a.
The title compound was also prepared from 4a in 51.2% yield according to the procedure used to prepare 7. 13 (11) The title compound was prepared starting from 9 in 21.3% yield according to the procedure used to prepare 5a. 13 The title compound was prepared starting from 10 in 56.6% yield according to the procedure used to prepare 5a. 13 C-7), 28.4 (C-4Ј), 22.7 (C-14) , 
Reaction of 4a with 4-phenylbutyric acid gave the title compound in 25.0% yield.
ES
To a solution of 2Ј-acetyl protected 4a (90 mg, 0.14 mmol) in DMF (0.5 ml) and toluene (0.5 ml) 4-aminophenyl isocyanate (70 mg, 4.2 mmol) was added. The solution was stirred under argon at 50°C for 4.5 hours and then at room temperature overnight. Water (10 ml) was added and the product extracted with CH 2 Cl 2 (2ϫ30 ml). Combined organic extracts were washed with brine (15 ml), dried over K 2 CO 3 and evaporated to dryness. The residue was purified by column chromatography (EtOAc -hexaneEt 2 N, 60 : 30 : 0.2) yielding 95 mg of 2Ј-acetyl protected 17 that after deprotection in MeOH (15 ml) at room temperature overnight gave the title compound (81 mg, 71.2%). Hydrolysis of 8a-aza-8a-homoerythromycin [18] , according to the procedure for preparation of 3a, resulted in 3-O-decladinosyl-8a-aza-8a-homoerythromycin [19] which reacted with 4-nitrophenyl acetic acid to give the title compound in 80.3% yield. 
